Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022Â Financial Results
Prioritizing Development of CPI-818 for T Cell Lymphomas, Autoimmune and Allergic Diseases Plans to Begin Phase 2 Clinical Trial of Ciforadenant in...
Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research
BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage...
Corvus Pharmaceuticals Provides Program Updates at R&D Symposium
Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas Program covers scientific rationale, preclinical...